Datopotamab Deruxtecan, often abbreviated as DATO, represents a notable advancement regarding targeted cancer therapy. This new antibody-drug conjugate joins a monoclonal antibody specifically focused on HER-2 https://xanderxmtq666048.activoblog.com/51385217/data-deruxtecan-an-encouraging-antibody-drug-conjugate